Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Die Pathologie
Erschienen in: Der Pathologe 1/2019

01.02.2019 | Endometriumkarzinom | Schwerpunkt: Gynäkopathologie

S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms

Anforderungen an die Pathologie

verfasst von: Prof. Dr. L.-C. Horn, G. Emons, S. Aretz, N. Bock, M. Follmann, S. Lax, M. Nothacker, E. Steiner, D. Mayr, Deutsche Krebsgesellschaft (DKG), Kommission zur Erstellung der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“

Erschienen in: Die Pathologie | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende Übersicht fasst die relevanten Aspekte der S3-Leitlinie Endometriumkarzinom zusammen. Die Empfehlungen umfassen die Aufarbeitung und Befunderhebung bei Abrasionen und Präparaten der (radikalen) Hysterektomie sowie der Lymphonodektomien, einschließlich der Sentinel-Lymphknoten-Diagnostik. Die Leitlinie berücksichtigt neben praktischen Aspekten der Pathologie ebenso die klinischen Notwendigkeiten an die Histopathologie für eine optimale operative, strahlentherapeutische und adjuvante Therapie der Patientinnen. Karzinosarkome werde als besondere Variante dem Endometriumkarzinom zugeordnet. Erstmals wird ein Algorithmus zur Diagnostik des Lynch-Syndroms bei Patientinnen mit einem Endometriumkarzinoms definiert. Zusätzlich werden morphologische Prognosefaktoren zusammengefasst.
Literatur
1.
Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, Iasonos A (2010) A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 116(3):399–403PubMedCrossRef
2.
Ahmed QF, Gattoc L, Al-Wahab Z, Abdulfatah E, Ruterbusch JJ, Cote M, Bandyopadhyay S, Morris RT, Ali-Fehmi R (2015) Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact. Am J Surg Pathol 39(2):221–226PubMedCrossRef
3.
Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26:115–123PubMedCrossRef
4.
Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG (2005) Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 29(10):1316–1321PubMedCrossRef
5.
Argani P, Cimino-Mathews A (2014) Intraoperative frozen sections. Diagnostic pitfalls. demosMedical, New York, S 255–258
6.
7.
8.
Bartosch C, Lopes MJ, Oliva E (2011) Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 18(6):415–437PubMedCrossRef
9.
Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O, Raimond E, Touboul C, Collinet P, Bleu G, Daraï E, Ballester M (2014) A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. Ann Surg Oncol 21(13):4239–4245PubMedCrossRef
10.
Bendifallah S, Canlorbe G, Raimond E, Bazire L, Huguet F, Graesslin O, Rouzier R, Darai E, Ballester M (2013) An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer 109(6):1498–1503PubMedPubMedCentralCrossRef
11.
Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN (2016) Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol 141(1):148–154PubMedCrossRef
12.
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17PubMedCrossRef
13.
Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA (2015) Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51(13):1742–1750PubMedCrossRef
14.
Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F (2013) French Cowden Disease Network, High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 50(4):255–263PubMedCrossRef
15.
Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB (2014) Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 32(2):90–100PubMedCrossRef
16.
SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Shahin AF, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endmetrial cancer: a review and current management strategies: part I. Gynecol Oncol 134(2):385–392CrossRef
17.
SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 134(2):393–402CrossRef
18.
Burleigh A, Talhouk A, Gilks CB, McAlpine JN (2015) Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol 138(1):141–146PubMedCrossRef
19.
Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: A review of the literature. Gynecol Oncol 137(3):581–588PubMedCrossRef
20.
21.
Chattopadhyay S, Galaal KA, Patel A, Fisher A, Nayar A, Cross P, Naik R (2012) Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer. BJOG 119(10):1162–1170PubMedCrossRef
22.
Clarke BA, Cooper K (2012) Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 19(4):231–238PubMedCrossRef
23.
Clarke BA, Gilks CB (2010) Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 63(5):410–415PubMedCrossRef
24.
Cole AJ, Quick CM (2013) Patterns of myoinvasion in endometrial adenocarcinoma: recognition and implications. Adv Anat Pathol 20(3):141–147PubMedCrossRef
25.
Colgan TJ, Hirschowitz L, Kim I, McCluggage WG (2014) Neuroendocrine tumours of the uterine cervix. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC Press, Lyon, S 196–198
26.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C (2016) ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1):16–41PubMedCrossRef
27.
Cox Bauer CM, Greer DM, Kram JJ, Kamelle SA (2016) Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer. Gynecol Oncol 141(2):199–205PubMedCrossRef
28.
Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P (2015) Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 91(3):530–539PubMedCrossRef
29.
Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW (2015) Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd 75(10):1028–1042PubMedPubMedCentralCrossRef
30.
Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sánchez-Heras AB, Castillejo MI, Rojas E, Barberá VM, Cigüenza S, Lopez JA, Piñero O, Román MJ, Martínez-Escoriza JC, Guarinos C, Perez-Carbonell L, Aranda FI, Soto JL (2013) Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS ONE 8(11):e79737PubMedPubMedCentralCrossRef
31.
Elshaikh MA, Al-Wahab Z, Mahdi H, Albuquerque K, Mahan M, Kehoe SM, Ali-Fehmi R, Rose PG, Munkarah AR (2015) Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 136(2):235–239PubMedCrossRef
32.
Euscher E, Fox P, Bassett R, Al-Ghawi H, Ali-Fehmi R, Barbuto D, Djordjevic B, Frauenhoffer E, Kim I, Hong SR, Montiel D, Moschiano E, Roma A, Silva E, Malpica A (2013) The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol 37(11):1728–1736PubMedPubMedCentralCrossRef
33.
Ferguson SE, Aronson M, Pollett A, Eiriksson LR, Oza AM, Gallinger S, Lerner-Ellis J, Alvandi Z, Bernardini MQ, MacKay HJ, Mojtahedi G, Tone AA, Massey C, Clarke BA (2014) Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 120(24):3932–3939PubMedCrossRef
34.
Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31(11):1653–1661PubMedCrossRef
35.
Ferraioli D, Chopin N, Beurrier F, Carrabin N, Buenerd A, Mathevet P (2015) The incidence and clinical significance of the micrometastases in the sentinel lymph nodes during surgical staging for early endometrial cancer. Int J Gynecol Cancer 25(4):673–680PubMedCrossRef
36.
Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T (2000) Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60(1):114–120PubMed
37.
Galic V, Schiavone MB, Herzog TJ, Holcomb K, Lewin SN, Lu YS, Neugut AI, Hershman DL, Wright JD (2013) Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest 31(7):500–504PubMedPubMedCentralCrossRef
38.
Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Bulten J, Visscher DW, Dowdy SC, Massuger LF (2012) Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis. Obstet Gynecol 120(5):1124–1131PubMed
39.
Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Massuger LF (2013) Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50. Gynecol Oncol 129(2):285–291PubMedCrossRef
40.
Geels YP, van der Putten LJ, van Tilborg AA, Lurkin I, Zwarthoff EC, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Visscher DW, Dowdy SC, Massuger LF (2015) Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol 137(2):245–251PubMedCrossRef
41.
Gungorduk K, Ozdemir A, Ertas IE, Selcuk I, Solmaz U, Ozgu E, Mat E, Gokcu M, Karadeniz T, Akbay S, Sanci M, Meydanli MM, Ayaz D, Gungor T (2015) Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol 20(4):782–789PubMedCrossRef
42.
Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817PubMedCrossRef
43.
Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, LaJeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, de la Chapelle A, Frankel W, Penzone P, Cohn DE, Copeland L, Eaton L, Fowler J, Lombardi J, Dunn P, Bell J, Reid G, Lewandowski G, Vaccarello L (2007) Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 67(19):9603PubMedCrossRef
44.
Han G, Lim D, Leitao MM Jr, Abu-Rustum NR, Soslow RA (2014) Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology 64(3):389–398PubMedCrossRef
45.
Hanley KZ, Fadare O, Fisher KE, Atkins KA, Mosunjac MB (2016) Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp. Int J Gynecol Pathol 35(3):249–255PubMedCrossRef
46.
Hertel JD, Huettner PC, Pfeifer JD (2014) Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol 33(2):127–134PubMedCrossRef
47.
Hirschowitz L, Nucci M, Zaino RJ (2013) Problematic issues in the staging of endometrial, cervical and vulval carcinomas. Histopathology 62(1):176–202PubMedCrossRef
48.
Hoekstra AV, Kim RJ, Small W Jr, Rademaker AW, Helenowski IB, Singh DK, Schink JC, Lurain JR (2009) FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol Oncol 114(2):273–278PubMedCrossRef
49.
Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, Schmidt D, German Cancer Society (2015) S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology. Pathologe 36(6):585–593PubMedCrossRef
50.
Horn LC, Dallacker M, Bilek K (2009) Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors. Pathologe 30(4):292–301PubMedCrossRef
51.
Horn LC, Mayr D, Brambs CE, Einenkel J, Sändig I, Schierle K (2016) Grading of gynecological tumors : current aspects. Pathologe 37(4):337–351PubMedCrossRef
52.
Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J (2004) Risk of progression in complex an atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14(2):348–353PubMedCrossRef
53.
Horn LC, Trost M, Bilek K (2010) Staging of endometrial carcinoma: aspects of ovarian and cervical involvement. Int J Gynecol Pathol 29(1):63–66PubMedCrossRef
54.
Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A (2013) Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol 130(3):463–469PubMedCrossRef
55.
Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112(3):537–542PubMedCrossRef
56.
Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL, Wright JD (2016) Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer. Gynecol Oncol 140(3):387–393PubMedPubMedCentralCrossRef
57.
Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG (2010) Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol 18(2):138–143PubMedCrossRef
58.
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339PubMedPubMedCentralCrossRef
59.
Kim HJ, Kim TJ, Song T, Kim MK, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG (2012) Patterns of recurrence in endometrial cancer patients at risk of lymph node metastasis or recurrence according to extent of lymphadenectomy. Int J Gynecol Cancer 22(4):611–616PubMedCrossRef
60.
Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A (2018) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 29(5):1180–1188PubMedCrossRef
61.
Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S (2018) L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 119(4):480–486PubMedCrossRef
62.
Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM (2012) Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 104(19):1503–1513PubMedPubMedCentralCrossRef
63.
Kumar S, Bandyopadhyay S, Semaan A, Shah JP, Mahdi H, Morris R, Munkarah A, Ali-Fehmi R (2011) The role of frozen section in surgical staging of low risk endometrial cancer. PLoS ONE 6(9):e21912PubMedPubMedCentralCrossRef
64.
Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56(2):403–412PubMedCrossRef
65.
Kyrgiou M, Chatterjee J, Lyus R, Amin T, Ghaem-Maghami S (2013) The role of cytology and other prognostic factors in endometrial cancer. J Obstet Gynaecol 33(7):729–734PubMedCrossRef
66.
Lacey JV Jr, Chia VM (2009) Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 63(1):39–44PubMedCrossRef
67.
Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, Hoedemaeker RF, van den Ouweland AM, Hulspas SM, Dubbink HJ, Kuipers EJ, Wagner A, Dinjens WN, Steyerberg EW (2012) Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 125(2):414–420PubMedCrossRef
68.
Lopez-Garcia MA, Palacios J (2010) Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 27(4):274–286PubMedCrossRef
69.
Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105(3):569–574PubMedCrossRef
70.
Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158–5164PubMedCrossRef
71.
Mahdi H, Mester JL, Nizialek EA, Ngeow J, Michener C, Eng C (2015) Germline PTEN, SDHB-D, and KLLN Alterations in Endometrial Cancer Patients With Cowden and Cowden-Like Syndromes: An International, Multicenter, Prospective Study. Cancer 121(5):688–696PubMedCrossRef
72.
Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P, Prat J (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32(6):569–577PubMedCrossRef
73.
Mauland KK, Wik E, Salvesen HB (2014) Clinical value of DNA content assessment in endometrial cancer. Cytometry B Clin Cytom 86(3):154–163PubMedCrossRef
74.
McCluggage WG, Colgan T, Duggan M, Hacker NF, Mulvany N, Otis C, Wilkinson N, Zaino RJ, Hirschowitz L (2013) Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol 32(1):45–65PubMedCrossRef
75.
McCluggage WG, Hirschowitz L, Wilson GE, Oliva E, Soslow RA, Zaino RJ (2011) Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. Am J Surg Pathol 35(2):289–294PubMedCrossRef
76.
McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28(8):1101–1122PubMedCrossRef
77.
Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236PubMedCrossRef
78.
Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, Köbel M (2014) POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 134(1):15–19PubMedCrossRef
79.
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108PubMedCrossRef
80.
81.
Nakao Y, Yamasaki F, Yokoyama M, Aihara S, Yasunaga M, Iwasaka T (2014) Minimal deviation endometrioid adenocarcinoma of the endometrium and its MRI findings. Eur J Gynaecol Oncol 35(2):185–187PubMed
82.
Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG (2009) Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol 113(3):316–323PubMedCrossRef
83.
Ozturk E, Dikensoy E, Balat O, Ugur MG, Aydin A (2012) Intraoperative frozen section is essential for assessment of myometrial invasion but not for histologic grade confirmation in endometrial cancer: a ten-year experience. Arch Gynecol Obstet 285(5):1415–1419PubMedCrossRef
84.
Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, Bosacki C, Jacquin JP, Levy A, Chauleur C, Magné N, Merrouche Y (2015) Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol 38(3):272–277PubMedCrossRef
85.
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef
86.
Pocrnich CE, Ramalingam P, Euscher ED, Malpica A (2016) Neuroendocrine carcinoma of the endometrium: a clinicopathologic study of 25 cases. Am J Surg Pathol 40(5):577–586PubMedPubMedCentralCrossRef
87.
Pollom EL, Conklin CM, von Eyben R, Folkins AK, Kidd EA (2016) Nomogram to predict risk of lymph node metastases in patients with endometrioid endometrial cancer. Int J Gynecol Pathol 35(5):395–401PubMedCrossRef
88.
Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2012) Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 23(5):1178–1184PubMedCrossRef
89.
Quddus MR, Sung CJ, Zhang C, Lawrence WD (2010) Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci 17(7):673–678PubMedCrossRef
90.
Robboy SJ, Mutter GL, Shako-Levy R, Bean SM, Prat J, Bentley RC, Russel P (2009) Cutup—gross description and processing of specimens. In: Robboy SJ, Mutter GL, Prat J, Bentley RC, Russel P, Anderson MC (Hrsg) Robboy’s pathology of the female reproductive tract. Elsevier, Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto, S 979–991CrossRef
91.
Roelofsen T, van Ham MA, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LF, Bulten J (2012) Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 120(6):1371–1381PubMedCrossRef
92.
Rauh-Hain JA, Vargas RJ, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG (2016) Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis. Am J Clin Oncol 39(1):43–48PubMedCrossRef
93.
Sakai K, Yamagami W, Susumu N, Nomura H, Kataoka F, Banno K, Tsuda H, Aoki D (2015) Pathological factors associated with omental metastases in endometrial cancer. Eur J Gynaecol Oncol 36(4):397–401PubMed
94.
SGO Society of Gynecologic Oncologists (2005) Clinical practice committee statement on prohpylactic salpingo-oophorectomy. Gynecol Oncol 98:179–181CrossRef
95.
Shaw PA, Clarke BA (2016) Prophylactic gynecologic specimens from hereditary cancer carriers. Surg Pathol Clin 9(2):307–328PubMedCrossRef
96.
Shiozaki T, Tabata T, Yamada T, Yamamoto Y, Yamawaki T, Ikeda T (2014) Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature. Int J Gynecol Cancer 24(3):549–555PubMedCrossRef
97.
Sho T, Hachisuga T, Nguyen TT, Urabe R, Kurita T, Kagami S, Kawagoe T, Matsuura Y, Shimajiri S (2014) Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer 24(1):102–106PubMedCrossRef
98.
Singh R (2014) Review literature on uterine carcinosarcoma. J Cancer Res Ther 10(3):461–468PubMed
99.
Soslow RA (2013) High-grade endometrial carcinomas—strategies for typing. Histopathology 62(1):89–110PubMedCrossRef
100.
Skala SL, Hagemann IS (2015) Optimal sampling of grossly normal omentum in staging of gynecologic malignancies. Int J Gynecol Pathol 34(3):281–287PubMedCrossRef
101.
Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2014) A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 18(58):1–406PubMedPubMedCentralCrossRef
102.
Clair StCM, Eriksson AG, Ducie JA, Jewell EL, Alektiar KM, Hensley ML, Soslow RA, Abu-Rustum NR, Leitao MM Jr (2016) Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 23(5):1653–1659CrossRef
103.
Steiner E, Einenkel J, Schmidt D, Horn LC (2012) Prädiktive und prognostische Marker beim Endometriumkarzinom. Onkologe 18:853–865CrossRef
104.
Stephan JM, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes HD, Button A, Goodheart MJ (2014) Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol 133(3):499–505PubMedCrossRef
105.
Syed S, Reed N, Millan D (2015) Adequacy of cervical sampling in hysterectomy specimens for endometrial cancer. Ann Diagn Pathol 19(2):43–44PubMedCrossRef
106.
Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M (2013) Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 109(7):1760–1765PubMedPubMedCentralCrossRef
107.
Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Köbel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN (2016) Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol 143(1):46–53PubMedPubMedCentralCrossRef
108.
Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802–813PubMedCrossRef
109.
110.
Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G, Gómez JF (2013) Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther 9:1305–1313PubMed
111.
Todo Y, Kato H, Okamoto K, Minobe S, Yamashiro K, Sakuragi N (2016) Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. J Gynecol Oncol 27(1):e1PubMedCrossRef
112.
Torres ML, Weaver AL, Kumar S, Uccella S, Famuyide AO, Cliby WA, Dowdy SC, Gostout BS, Mariani A (2012) Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 120(5):998–1004PubMedPubMedCentral
113.
Touboul C, Bentivegna E, Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, Morice P (2013) Sentinel lymph node in endometrial cancer: a review. Curr Oncol Rep 15(6):559–565PubMedCrossRef
114.
Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL (2012) Society of gynecologic oncology clinical practice committee. Management of endometrial precancers. Obstet Gynecol 120(5):1160–1175PubMedPubMedCentral
115.
Turan T, Oguz E, Unlubilgin E, Tulunay G, Boran N, Demir OF, Kose MF (2013) Accuracy of frozen-section examination for myometrial invasion and grade in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 167(1):90–95PubMedCrossRef
116.
Ulker V, Tunca A, Numanoglu C, Akbayir O, Akyol A, Erim A, Ongut C (2014) Should omentectomy be a part of surgical staging in patients with endometrioid adenocarcinoma of the uterine corpus? Gynecol Obstet Invest 77(1):58–63PubMedCrossRef
117.
Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM 2nd (2014) Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 133(2):216–220PubMedCrossRef
118.
119.
Williams JW, Hirschowitz L (2006) Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas. Int J Gynecol Pathol 25(1):59–64PubMedCrossRef
120.
Wittekind C, Meyer HJ (2011) TNM-Klassifikation maligner Tumoren. Endometriumkarzinom. Wiley-Blackwell, Weinheim, S 198–202
121.
Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ (2012) Contemporary management of endometrial cancer. Lancet 379(9823):1352–1360PubMedCrossRef
122.
Zaino R, Carinelli SG, Ellenson LH, Rng C, Katabuchi H, Konishi I, Lax S, Matias-Giu X, Mutter GL, Peters WA, Sherman ME, Shih IM, Soslow R, Stewart CJR (2014) Epitehlail tumors and precursosr of the endometrium. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female Reporductive tract. IARC Press, Lyon, S 125–135
123.
Zaino RJ, Abendroth C, Yemelyanova A, Oliva E, Lim D, Soslow R, Delair D, Hagemann IS, Montone K, Zhu J (2013) Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecol Oncol 128(1):83–87PubMedCrossRef
124.
Zaino RJ (2009) FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28:1–9PubMedCrossRef
125.
Zaino RJ (2014) Unusual patterns of endometrial carcinoma including MELF and its relation to epithelial mesenchymal transition. Int J Gynecol Pathol 33(4):357–364PubMedCrossRef
126.
Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D (2013) The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 44(6):1047–1054PubMedCrossRef
127.
Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105(15):1142–1150PubMedCrossRef
128.
Zheng W, Schwartz PE (2005) Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 96(3):579–582PubMedCrossRef
129.
Zhu J, Wen H, Bi R, Wu X (2016) Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. J Gynecol Oncol 27(2):e18PubMedCrossRef
Metadaten
Titel
S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms
Anforderungen an die Pathologie
verfasst von
Prof. Dr. L.-C. Horn
G. Emons
S. Aretz
N. Bock
M. Follmann
S. Lax
M. Nothacker
E. Steiner
D. Mayr
Deutsche Krebsgesellschaft (DKG)
Kommission zur Erstellung der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“
Publikationsdatum
01.02.2019
Verlag
Springer Medizin
Erschienen in
Die Pathologie / Ausgabe 1/2019
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-019-0574-7

Weitere Artikel der Ausgabe 1/2019

Der Pathologe 1/2019 Zur Ausgabe

Editorial

Geschichte der Pathologie – von den ersten Obduktionen bis in die neuere Zukunft

Geschichte der Pathologie

Geschichte der anatomischen und klinischen Obduktion

Schwerpunkt: Gynäkopathologie

Fallstricke und Probleme bei der Differenzialdiagnose epithelialer Ovarialtumoren

In eigener Sache

Dank an die Gutachter von Der Pathologe

Editorial

40 Jahre Der Pathologe

Kasuistiken

Die intravenöse Leiomyomatose

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise